Immune-Boosting shot tested to save lives in severe pneumonia
NCT ID NCT07492875
Summary
This study is testing a new combination treatment designed to boost the immune system in critically ill adults with severe pneumonia, often complicated by sepsis or acute respiratory distress. The goal is to see if adding this immune therapy to standard hospital care can help more patients survive the first 28 days and reduce their need for ventilators and intensive care. The treatment involves two investigational agents: a drug (Nogapendekin Alfa Inbakicept) and a cell therapy (iNKT cells).
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SEPSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.